Paper
0
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Authors
Rashmi Murthy,Sherene Loi
Alicia Okines,Elisavet Paplomata,Erika Hamilton,Sara Hurvitz,Nancy Lin,Virginia Borges,Vandana Abramson,Carey Anders,Philippe Bédard,Mafalda Oliveira,Erik Jakobsen,Thomas Bachelot,Shlomit Shachar,Volkmar Müller,Sofía Braga,François Duhoux,Richard Greil,David Cameron,Lisa Carey,Giuseppe Curigliano,Karen Gelmon,Gabriel Hortobágyi,Ian Krop,Sibylle Loibl,Mark Pegram,Dennis Slamon,Maria Palanca-Wessels,Luke Walker,Wentao Feng,Eric Winer
+30 authors
,Philippe BedardPublished
Dec 11, 2019
Show more
Save
Tip0
TipSave
Abstract
Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.